FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381620004> ?p ?o ?g. }

• W4381620004 abstract "Abstract Study question Does giving women with polycystic ovarian syndrome (PCOS) preconception metformin and continuing it through at least the first trimester improve pregnancy outcomes? Summary answer Giving women with PCOS preconception metformin and continuing throughout the first trimester significantly reduces the risk of early miscarriage, and can improve pregnancy outcomes. What is known already Metformin, either alone or in combination with other ovulation induction agents, can improve ovulation and clinical pregnancy rates in women with PCOS. Its impact on miscarriage and live birth rate are less well understood. Furthermore the impact of both the timing and duration of metformin treatment on subsequent pregnancy outcomes, in women with PCOS, is unknown. We sought to evaluate the role that preconception metformin, continued until at least the point of positive pregnancy test, may have on pregnancy outcomes in women with PCOS and the effect that stopping metformin once pregnant might have. Study design, size, duration We conducted a systematic review and meta-analysis. A search within MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for studies listed from database inception to 13th October 2022 was conducted. Potentially eligible studies identified through other sources (such as the reference lists of the selected primary studies and review articles) were also screened for inclusion. We adopted Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for determining the quality of the evidence. Participants/materials, setting, methods The full-text of studies identified as being potentially suitable for inclusion were obtained. Those meeting the study selection criteria, outlined, were included in the systematic review and meta-analysis. Studies were included if they were prospective randomised controlled trials, comparing the use of metformin in women with PCOS, which had been started pre-conceptually and continued at least until pregnant (confirmed urinary pregnancy test), to either placebo or no treatment. Main results and the role of chance A total of 12 studies (1517 women) were included in the systematic review and meta-analysis. Women who were given preconception metformin which was continued until at least the end of the first trimester showed a significantly reduced risk of early miscarriage [OR 0.51 95% CI (0.27-0.96), 6 studies, n = 294, I2=0%], compared to either placebo or no treatment. Continuing preconception metformin until at least the end of first trimester also significantly increased clinical pregnancy rates [OR 1.92 95% CI (1.43-2.59), 5 studies, n = 793, I2=67%]. Only 3 studies, looked at live birth outcome which showed an increased odds of live birth in the metformin group, but this was not statistically significant [OR 1.38 95% CI (0.65-2.92), 3 studies, n = 212, I2=0%]. In women who stopped taking metformin following a positive pregnancy test, there was a suggestion of improvement in clinical pregnancy [OR 1.36 95% CI (0.99-1.87), 6 studies, n = 663, I2=45%] and live birth rates [OR 1.15 95% CI (0.57-2.35), 5 studies, n = 244, I2=0%]; but these were not statistically significant. Conversely, there was an increased odds of early miscarriage [OR 1.22 95% CI (0.59-2.52), 6 studies, n = 244, I2=0%], but this was also not statistically significant. Limitations, reasons for caution Whilst a role for commencing metformin pre-conceptually and continuing until at least the end of the first trimester has been demonstrated to be effective in improving clinical pregnancy rates and reducing miscarriage risk, the effectiveness and safety of continuing it throughout the remainder of the pregnancy remains unclear. Wider implications of the findings Continuing metformin treatment until at least the end of first trimester can increase the clinical pregnancy rate and reduce the risk of miscarriage. Stopping metformin once pregnant could be harmful and increase the risk of miscarriage. These findings should be considered when managing women with PCOS wishing to conceive. Trial registration number CRD42017073976" @default.
• W4381620004 created "2023-06-23" @default.
• W4381620004 creator A5034534650 @default.
• W4381620004 creator A5036708296 @default.
• W4381620004 creator A5054934848 @default.
• W4381620004 creator A5060414786 @default.
• W4381620004 creator A5087495070 @default.
• W4381620004 date "2023-06-01" @default.
• W4381620004 modified "2023-09-23" @default.
• W4381620004 title "P-665 Timing of metformin treatment in women with polycystic ovarian syndrome and associated pregnancy outcomes: a systematic review and meta-analysis" @default.
• W4381620004 doi "https://doi.org/10.1093/humrep/dead093.991" @default.
• W4381620004 hasPublicationYear "2023" @default.
• W4381620004 type Work @default.
• W4381620004 citedByCount "0" @default.
• W4381620004 crossrefType "journal-article" @default.
• W4381620004 hasAuthorship W4381620004A5034534650 @default.
• W4381620004 hasAuthorship W4381620004A5036708296 @default.
• W4381620004 hasAuthorship W4381620004A5054934848 @default.
• W4381620004 hasAuthorship W4381620004A5060414786 @default.
• W4381620004 hasAuthorship W4381620004A5087495070 @default.
• W4381620004 hasBestOaLocation W43816200041 @default.
• W4381620004 hasConcept C126322002 @default.
• W4381620004 hasConcept C131872663 @default.
• W4381620004 hasConcept C134018914 @default.
• W4381620004 hasConcept C17744445 @default.
• W4381620004 hasConcept C199539241 @default.
• W4381620004 hasConcept C2777391703 @default.
• W4381620004 hasConcept C2779234561 @default.
• W4381620004 hasConcept C2779245376 @default.
• W4381620004 hasConcept C2779473830 @default.
• W4381620004 hasConcept C2780323712 @default.
• W4381620004 hasConcept C29456083 @default.
• W4381620004 hasConcept C3018442814 @default.
• W4381620004 hasConcept C54355233 @default.
• W4381620004 hasConcept C555293320 @default.
• W4381620004 hasConcept C71924100 @default.
• W4381620004 hasConcept C86803240 @default.
• W4381620004 hasConcept C95190672 @default.
• W4381620004 hasConceptScore W4381620004C126322002 @default.
• W4381620004 hasConceptScore W4381620004C131872663 @default.
• W4381620004 hasConceptScore W4381620004C134018914 @default.
• W4381620004 hasConceptScore W4381620004C17744445 @default.
• W4381620004 hasConceptScore W4381620004C199539241 @default.
• W4381620004 hasConceptScore W4381620004C2777391703 @default.
• W4381620004 hasConceptScore W4381620004C2779234561 @default.
• W4381620004 hasConceptScore W4381620004C2779245376 @default.
• W4381620004 hasConceptScore W4381620004C2779473830 @default.
• W4381620004 hasConceptScore W4381620004C2780323712 @default.
• W4381620004 hasConceptScore W4381620004C29456083 @default.
• W4381620004 hasConceptScore W4381620004C3018442814 @default.
• W4381620004 hasConceptScore W4381620004C54355233 @default.
• W4381620004 hasConceptScore W4381620004C555293320 @default.
• W4381620004 hasConceptScore W4381620004C71924100 @default.
• W4381620004 hasConceptScore W4381620004C86803240 @default.
• W4381620004 hasConceptScore W4381620004C95190672 @default.
• W4381620004 hasIssue "Supplement_1" @default.
• W4381620004 hasLocation W43816200041 @default.
• W4381620004 hasOpenAccess W4381620004 @default.
• W4381620004 hasPrimaryLocation W43816200041 @default.
• W4381620004 hasRelatedWork W1571332341 @default.
• W4381620004 hasRelatedWork W2019873917 @default.
• W4381620004 hasRelatedWork W2048527301 @default.
• W4381620004 hasRelatedWork W2055842739 @default.
• W4381620004 hasRelatedWork W2124760769 @default.
• W4381620004 hasRelatedWork W2401739700 @default.
• W4381620004 hasRelatedWork W2594069839 @default.
• W4381620004 hasRelatedWork W2803263777 @default.
• W4381620004 hasRelatedWork W3029241048 @default.
• W4381620004 hasRelatedWork W2472105301 @default.
• W4381620004 hasVolume "38" @default.
• W4381620004 isParatext "false" @default.
• W4381620004 isRetracted "false" @default.
• W4381620004 workType "article" @default.